26 November 2014
ValiRx Plc
("ValiRx" or "the Company")
Approved Clinical Trial of VAL201
Re: Progress with the Trial
Recruitment and Testing
"A Phase I/II, dose escalation study to assess the safety and tolerability of VAL201 in patients with locally advanced or metastatic prostate cancer and other advanced solid tumours."
ValiRx Plc (AIM: VAL), the life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, is pleased to announce that, with recruitment and human testing underway, the Company is expecting to have the first results relating to safety and tolerability from the first subjects during Quarter 1, 2015.
Details of the trial can be found on clinicaltrials.gov, where they were posted as a legal requirement and part of the extensive work required to reach this step of human testing in the clinical development of VAL201.
Dr Satu Vainikka, CEO of ValiRx, commented: "It is a pleasure to show the development of VAL201 progressing and delivering according to schedule. I and the whole team remain committed and enthused by the project".
*** ENDS ***
For more information, please contact:
ValiRx plc |
Tel: +44 (0) 20 3008 4416 |
Dr Satu Vainikka |
www.valirx.com |
|
|
Cairn Financial Advisers LLP (Nominated Adviser) |
Tel: +44 (0) 20 7148 7900 |
Liam Murray / Avi Robinson |
|
|
|
Daniel Stewart & Company Plc (Broker) |
Tel: +44 (0) 20 7776 6550 |
Martin Lampshire / Mark Treharne |
|
Peckwater PR |
Tel: +44 (0) 7879 458 364 |
Tarquin Edwards |
[email protected] |
Notes to the editor
ValiRx Plc
ValiRx Plc is a biopharmaceutical company developing novel technologies and products in oncology therapeutics and diagnostics. The product focus is in the epigenomic analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases.
The Company listed on AIM in October 2006 and is creating a portfolio of innovative products through investment in specific development projects. It actively manages projects within this portfolio as a trading company and is not an investment vehicle. The ValiRx business model spreads the risks of life science technology developments by minimising financial exposure and running a set of projects to defined commercial endpoints. This maximises returns to shareholders by adding value at the earlier stages where value increases per investment unit are the greatest.
The Company operates through the following divisional companies:
1. ValiFinn is the biomarkers and diagnostic development division
2. ValiPharma is the therapeutics division with two embedded technologies primarily directed at the treatment of cancers.
